Sandbox:Polio prevention: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | OPV | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | OPV | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | *Monovalent (Serotype 2) <br> *Bivalent (Serotypes 1 & 3)‡ <br> *Trivalent (Serotypes 1, 2, & 3) | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | *Monovalent (Serotype 2) <br> *Bivalent (Serotypes 1 & 3)‡ <br> *Trivalent (Serotypes 1, 2, & 3) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | 3 to 4 doses | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | 3 to 4 doses | ||
| Line 22: | Line 21: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| IPV | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| IPV | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| *Serotype 1 <br> *Serotype 2 <br> *Serotype 3 | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| *Serotype 1 <br> *Serotype 2 <br> *Serotype 3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| 4 doses || || || || | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| 4 doses | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| ✔ | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| ✔ | ||
|- | |- | ||
Revision as of 16:12, 24 October 2016
| Vaccine Type | Serotypes covered | Number of Doses | Vaccination Schedule in Endemic and High Risk Countries† | ||||
|---|---|---|---|---|---|---|---|
| Birth | 6 weeks | 10 weeks | 14 weeks | ||||
| OPV | *Monovalent (Serotype 2) *Bivalent (Serotypes 1 & 3)‡ *Trivalent (Serotypes 1, 2, & 3) |
3 to 4 doses | ✔ | ✔ | ✔ | ✔ | |
| IPV | *Serotype 1 *Serotype 2 *Serotype 3 |
4 doses | ✔ | ||||
| † Countries at high risk for importation and subsequent spread | ‡ Countries at high risk for importation and subsequent spread | ||||||